Previous Section
Clinical Trials
1. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study.
- Author
- Walz J; Shariat SF; Suardi N; Perrotte P; Lotan Y; Palapattu GS; Gupta A; Bastian PJ; Rogers CG; Vazina A; Amiel GE; Sagalowsky AI; Schoenberg M; Lerner SP; Karakiewicz PI;
- Institution
- Cancer Prgonosis and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada.
- Journal
- BJU Int. 2008 Jun;101(11):1356-61.
- Abstract URL
- Click here to view abstract
2. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
- Author
- Dreicer R; Li H; Cooney MM; Wilding G; Roth BJ;
- Institution
- Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA. dreicer@ccf.org
- Journal
- Cancer. 2008 Jun 15;112(12):2671-5.
- Abstract URL
- Click here to view abstract
3. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
- Author
- Ojea A; Nogueira JL; Solsona E; Flores N; Gomez JM; Molina JR; Chantada V; Camacho JE; Pineiro LM; Rodriguez RH; Isorna S; Blas M; Martinez-Pineiro JA; Madero R; Ojea A; Nogueira JL; Solsona E; Flores N; Gomez JM; Molina JR; Chantada V; Camacho JE; Pineiro LM; Rodriguez RH; Isorna S; Blas M; Martinez-Pineiro JA; Madero R;
- Institution
- Complejo Hospitalario Universitario de Vigo, Vigo, Spain. aojea@retegal.es
- Journal
- Eur Urol. 2007 Nov;52(5):1398-406. Epub 2007 Apr 27.
- Abstract URL
- Click here to view abstract
4. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response van der Heijden AG, Moonen PM, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Barten EJ, Puri R, van Kalken CK, Witjes JA, University Medical Centre Nijmegen, Nijmegen, The Netherlands.
- Author
- Grossman HB;
- Institution
- Journal
- Urol Oncol. 2007 May-Jun;25(3):271-2.
- Abstract URL
- Click here to view abstract
5. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
- Author
- Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS;
- Institution
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
- Journal
- Urology. 2007 Mar;69(3):479-84.
- Abstract URL
- Click here to view abstract
6. Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer.
- Author
- Naito S; Koga H; Yamaguchi A; Fujimoto N; Hasui Y; Kuramoto H; Iguchi A; Kinukawa N;
- Institution
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Journal
- J Urol. 2008 Feb;179(2):485-90.
- Abstract URL
- Click here to view abstract
7. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience.
- Author
- Perdona S; Autorino R; Damiano R; De Sio M; Morrica B; Gallo L; Silvestro G; Farella A; De Placido S; Di Lorenzo G;
- Institution
- Comprehensive Urology Unit, National Tumor Institute, G. Pascale Foundation, Naples, Italy.
- Journal
- Cancer. 2008 Jan 1;112(1):75-83.
- Abstract URL
- Click here to view abstract
8. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.
- Author
- Kotwal S; Choudhury A; Johnston C; Paul AB; Whelan P; Kiltie AE;
- Institution
- Pyrah Department of Urology, St. James's University Hospital, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
- Journal
- Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):456-63. Epub 2007 Sep 27.
- Abstract URL
- Click here to view abstract
9. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
- Author
- Lin CC; Hsu CH; Huang CY; Keng HY; Tsai YC; Huang KH; Cheng AL; Pu YS;
- Institution
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, ROC.
- Journal
- Anticancer Drugs. 2007 Apr;18(4):487-91.
- Abstract URL
- Click here to view abstract
Next: Radiation Therapy
